Hims & Hers Health (NYSE:HIMS) CFO Sells $275,092.78 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78. Following the transaction, the chief financial officer directly owned 91,617 shares of the company’s stock, valued at approximately $2,779,659.78. This trade represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.79, for a total value of $306,475.30.
• On Monday, December 22nd, Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.72, for a total transaction of $824,774.80.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total value of $853,513.47.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.81, for a total value of $853,513.47.

Hims & Hers Health Stock Down 5.4%

Shares of NYSE HIMS traded down $1.64 during mid-day trading on Wednesday, reaching $28.83. The company had a trading volume of 27,825,825 shares, compared to its average volume of 17,159,578. The stock has a market cap of $6.56 billion, a P/E ratio of 53.39, a PEG ratio of 5.32 and a beta of 2.37. Hims & Hers Health, Inc. has a 52-week low of $23.97 and a 52-week high of $72.98. The firm has a 50 day simple moving average of $35.41 and a two-hundred day simple moving average of $45.43. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 EPS. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a share buyback plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 4.5% in the third quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock worth $1,107,062,000 after acquiring an additional 844,991 shares during the last quarter. Capital World Investors grew its stake in shares of Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the last quarter. State Street Corp increased its holdings in shares of Hims & Hers Health by 1.9% during the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock worth $406,865,000 after buying an additional 132,384 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Hims & Hers Health by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock worth $236,622,000 after buying an additional 71,593 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Evercore ISI started coverage on Hims & Hers Health in a research note on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective for the company. KeyCorp began coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating on the stock. Barclays began coverage on Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, UBS Group set a $32.00 price target on Hims & Hers Health in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $44.54.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.